NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.

Founder, Chief Scientific Officer, Member of Executive Board & Director

Mr. Jim  Jacobson

Chief Legal Officer & Secretary

Mr. Douglas F. Kling

Chief Operating Officer

Ms. Juliette  Audet M.B.A., M.Sc.

Chief Business Officer

Ms. Annie  Neild

Vice President & Head of Regulatory Affairs

Mr. William  Jones Jr., M.B.A.

Chief Commercial Officer

Mr. Mayur Amrat Somaiya

Chief Financial Officer

Dr. Marc  Ditmarsch M.D.

Chief Development Officer

Dr. Sheng  Cui Ph.D.

Vice President & Head of Chemistry Manufacturing and Controls (CMC)

Dr. Michael Harvey Davidson FACC, Facp., M.D.

Chief Executive Officer, President, Executive Board Member & Director

Biotechnologie

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. Structure de gestion

Informations sur la direction